AGP Executive Report
Last update: 11 hours agoAI in Medicine: Alibaba open-sourced Damo Radar, a vision-language model that flags nearly 150 abdominal conditions from contrast CT scans, aiming to cut missed diagnoses by 10% and speed reads by 30%+—a big step for faster, more consistent imaging support. US–China Pharma Rules: Reuters reports the U.S. is drafting rules that could preserve most licensing deals for Chinese drugs, while tightening national-security guardrails around pathogen/weaponizable biotech. China Biotech Push: China’s MIIT unveiled a 2026-2030 plan targeting 25% of first-in-class drugs to originate in China and growing biotech output to 3.5 trillion yuan by 2030. Medical Tourism: Jiahui Health says inbound medical tourism is surging, citing 1.28 million international patient visits in 2025 and policy/visa facilitation as key drivers. Public Health & Safety: U.S. states and regulators are cracking down on counterfeit GLP-1s tied to Chinese supply chains, while China also drafts guidelines to protect minors online with “minor mode” restrictions. Wellness Market: Elite Asia Group launched an integrative TCM center blending AI with acupuncture/cupping and an “AI Mugwort Robot” for moxibustion.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
